Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]
In development
Reference number: GID-TA11340
Expected publication date: TBC
NICE has been made aware of some inconsistencies regarding the appeal process for this appraisal.
As a result, the publication of final guidance will be delayed and consultees will have the opportunity to submit appeals until 5pm Thursday 10 July.